1.1 USD
+0.01 (+0.92%)
1.09 USD
-0.01 (-0.91%)
We assign a fundamental rating of 2 out of 10 to SCTL. SCTL was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCTL have multiple concerns. SCTL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SCTL had negative earnings in the past year.
In the past year SCTL has reported a negative cash flow from operations.
SCTL had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: SCTL reported negative operating cash flow in multiple years.
1.2 Ratios
SCTL has a better Return On Assets (-8.64%) than 74.37% of its industry peers.
Looking at the Return On Equity, with a value of -22.61%, SCTL is in the better half of the industry, outperforming 72.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.64% | ||
| ROE | -22.61% | ||
| ROIC | N/A |
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SCTL's Gross Margin of 19.17% is in line compared to the rest of the industry. SCTL outperforms 49.75% of its industry peers.
In the last couple of years the Gross Margin of SCTL has declined.
SCTL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
2. Health
2.1 Basic Checks
SCTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SCTL has been increased compared to 1 year ago.
SCTL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SCTL has been reduced compared to a year ago.
2.2 Solvency
SCTL has an Altman-Z score of -1.24. This is a bad value and indicates that SCTL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.24, SCTL is in line with its industry, outperforming 48.74% of the companies in the same industry.
SCTL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, SCTL is in line with its industry, outperforming 55.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.24 |
ROIC/WACCN/A
WACC11.28%
2.3 Liquidity
SCTL has a Current Ratio of 1.07. This is a normal value and indicates that SCTL is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SCTL (1.07) is worse than 85.93% of its industry peers.
SCTL has a Quick Ratio of 1.07. This is a bad value and indicates that SCTL is not financially healthy enough and could expect problems in meeting its short term obligations.
SCTL has a Quick ratio of 0.86. This is amonst the worse of the industry: SCTL underperforms 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.07 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
SCTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.74%, which is quite impressive.
The Revenue has been growing slightly by 4.91% in the past year.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%
3.2 Future
The Earnings Per Share is expected to grow by 31.13% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.11% on average over the next years. This is quite good.
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SCTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SCTL is valued a bit cheaper than 78.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 27.26 |
4.3 Compensation for Growth
A more expensive valuation may be justified as SCTL's earnings are expected to grow with 31.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y31.13%
5. Dividend
5.1 Amount
No dividends for SCTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.1
+0.01 (+0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner Change0%
Market Cap116.26M
Revenue(TTM)94.64M
Net Income(TTM)-13.27M
Analysts78
Price Target1.12 (1.82%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-71.57%
Min EPS beat(2)-145.1%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-44.61%
Min EPS beat(4)-145.1%
Max EPS beat(4)1.96%
EPS beat(8)5
Avg EPS beat(8)-15.62%
EPS beat(12)9
Avg EPS beat(12)5.08%
EPS beat(16)10
Avg EPS beat(16)-57.49%
Revenue beat(2)1
Avg Revenue beat(2)0.76%
Min Revenue beat(2)-4.6%
Max Revenue beat(2)6.12%
Revenue beat(4)2
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-4.6%
Max Revenue beat(4)6.12%
Revenue beat(8)4
Avg Revenue beat(8)2%
Revenue beat(12)7
Avg Revenue beat(12)1.72%
Revenue beat(16)9
Avg Revenue beat(16)-0.52%
PT rev (1m)-47.2%
PT rev (3m)-47.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.98 | ||
| P/tB | 7.58 | ||
| EV/EBITDA | 27.26 |
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.9
BVpS0.56
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.64% | ||
| ROE | -22.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.17% | ||
| FCFM | N/A |
ROA(3y)-9.46%
ROA(5y)-14.37%
ROE(3y)-27.61%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y-15.39%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 92.47% | ||
| Cap/Sales | 8.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.07 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | -1.24 |
F-Score4
WACC11.28%
ROIC/WACCN/A
Cap/Depr(3y)87.57%
Cap/Depr(5y)90.2%
Cap/Sales(3y)8.33%
Cap/Sales(5y)8.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
EPS Next Y45.81%
EPS Next 2Y27.18%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue 1Y (TTM)4.91%
Revenue growth 3Y12.48%
Revenue growth 5Y4.12%
Sales Q2Q%14.16%
Revenue Next Year2.59%
Revenue Next 2Y4.69%
Revenue Next 3Y6.13%
Revenue Next 5Y9.11%
EBIT growth 1Y-1334.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year472.86%
EBIT Next 3Y112.66%
EBIT Next 5YN/A
FCF growth 1Y22.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.39%
OCF growth 3YN/A
OCF growth 5YN/A
SOCIETAL CDMO INC / SCTL FAQ
Can you provide the ChartMill fundamental rating for SOCIETAL CDMO INC?
ChartMill assigns a fundamental rating of 2 / 10 to SCTL.
What is the valuation status for SCTL stock?
ChartMill assigns a valuation rating of 1 / 10 to SOCIETAL CDMO INC (SCTL). This can be considered as Overvalued.
How profitable is SOCIETAL CDMO INC (SCTL) stock?
SOCIETAL CDMO INC (SCTL) has a profitability rating of 2 / 10.
What is the expected EPS growth for SOCIETAL CDMO INC (SCTL) stock?
The Earnings per Share (EPS) of SOCIETAL CDMO INC (SCTL) is expected to grow by 45.81% in the next year.